COX-2-selective inhibitors in the treatment of arthritis

摘要: Therapy with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) has long been the cornerstone of pharmacologic management patients osteoarthritis (OA) and rheumatoid arthritis (RA). Many OA or RA, however, are at increased risk developing clinically significant adverse events associated NSAID therapy, particularly upper gastrointestinal (GI) complications including symptomatic complicated ulcers. The introduction cyclooxygenase (COX)-2-selective inhibitors (coxibs) represents a major advance in approach to signs symptoms arthritis. In addition first two members this class, celecoxib rofecoxib, other coxibs have introduced development (valdecoxib, etoricoxib). numerous clinical trials, shown be as effective NSAIDs relieving pain inflammation notably, significantly lower NSAID-type events. use treat RA is recommended first-line therapy when present vulnerable potential NSAID-associated GI toxicity.